By Stephen Nakrosis
Shares of Humacyte fell in post-market trading after the company said it was selling additional shares of its common stock.
The biotechnology company's shares were down 20% to $2.31 following the close, putting them below the 52-week low of $2.75 set on March 13. The stock ended the market session down 13% at $2.87.
Proceeds from the offering are slated to fund the commercialization of Symvess in the vascular trauma indication, development of product candidates in the company's pipeline, and for working capital and general corporate purposes, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 25, 2025 18:15 ET (22:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。